Platinum-based chemotherapy in metastatic prostate cancer : what possibilities?
© 2023. The Author(s)..
Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen deprivation therapy remains the cornerstone of prostate cancer treatment, but novel approaches are needed for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have highlighted the prevalence of mutations in DNA repair genes, including BRCA1 and BRCA2, in mCRPC patients, rendering them more susceptible to platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors. Platinum-based chemotherapy, particularly in combination with taxanes, has demonstrated encouraging activity in mCRPC, as well as homologous recombination gene alterations have shown increased sensitivity to platinum compounds in these patients. The combination of platinum-based chemotherapy with PARP inhibitors represents a novel and potentially effective therapeutic strategy for this subgroup of patients. However, the optimal sequence of administering these agents and the potential for cross-resistance and cross-toxicities remain areas requiring further investigation. Prospective randomized studies are essential to elucidate the most effective treatment approach for this challenging patient population. This review aims to explore the potential of platinum-based chemotherapy in the context of prostate cancer, and more in detail in homologous recombination repair (HRR) mutated patients. We discuss the synergistic effects of combining platinum compounds with PARP inhibitors and the potential benefits of adopting specific therapeutic sequences.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Cancer chemotherapy and pharmacology - 93(2024), 1 vom: 01. Jan., Seite 1-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Catalano, Martina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00280-023-04604-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364260564 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364260564 | ||
| 003 | DE-627 | ||
| 005 | 20240313233751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00280-023-04604-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM364260564 | ||
| 035 | |a (NLM)37934252 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Catalano, Martina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platinum-based chemotherapy in metastatic prostate cancer |b what possibilities? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Metastatic prostate cancer is a major health burden worldwide, necessitating the continuous development of effective treatment strategies. Androgen deprivation therapy remains the cornerstone of prostate cancer treatment, but novel approaches are needed for metastatic castration-resistant prostate cancer (mCRPC). Recent studies have highlighted the prevalence of mutations in DNA repair genes, including BRCA1 and BRCA2, in mCRPC patients, rendering them more susceptible to platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors. Platinum-based chemotherapy, particularly in combination with taxanes, has demonstrated encouraging activity in mCRPC, as well as homologous recombination gene alterations have shown increased sensitivity to platinum compounds in these patients. The combination of platinum-based chemotherapy with PARP inhibitors represents a novel and potentially effective therapeutic strategy for this subgroup of patients. However, the optimal sequence of administering these agents and the potential for cross-resistance and cross-toxicities remain areas requiring further investigation. Prospective randomized studies are essential to elucidate the most effective treatment approach for this challenging patient population. This review aims to explore the potential of platinum-based chemotherapy in the context of prostate cancer, and more in detail in homologous recombination repair (HRR) mutated patients. We discuss the synergistic effects of combining platinum compounds with PARP inhibitors and the potential benefits of adopting specific therapeutic sequences | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Combination therapy | |
| 650 | 4 | |a DNA damage repair | |
| 650 | 4 | |a Metastatic prostate cancer | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a Platinum-based chemotherapy | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 650 | 7 | |a Platinum Compounds |2 NLM | |
| 700 | 1 | |a Lapucci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Nobili, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a De Gennaro Aquino, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Vascotto, Ismaela Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Antonuzzo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Villari, Donata |e verfasserin |4 aut | |
| 700 | 1 | |a Nesi, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Mini, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Roviello, Giandomenico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d 1990 |g 93(2024), 1 vom: 01. Jan., Seite 1-9 |w (DE-627)NLM00036438X |x 1432-0843 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:1-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00280-023-04604-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2024 |e 1 |b 01 |c 01 |h 1-9 | ||